Dimensional Fund Advisors LP boosted its position in shares of Aytu BioPharma, Inc. (NASDAQ:AYTU – Free Report) by 54.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,551 shares of the company’s stock after acquiring an additional 8,311 shares during the period. Dimensional Fund Advisors LP owned 0.39% of Aytu BioPharma worth $69,000 at the end of the most recent quarter.
Aytu BioPharma Stock Up 1.3 %
Shares of AYTU opened at $2.29 on Wednesday. The company has a 50-day simple moving average of $2.44 and a 200-day simple moving average of $2.76. The firm has a market capitalization of $13.68 million, a P/E ratio of -0.87 and a beta of -1.43. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.79 and a current ratio of 0.99. Aytu BioPharma, Inc. has a 52 week low of $2.11 and a 52 week high of $3.50.
Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last issued its quarterly earnings data on Thursday, September 26th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.37). Aytu BioPharma had a negative return on equity of 51.31% and a negative net margin of 19.56%. The firm had revenue of $17.98 million for the quarter.
About Aytu BioPharma
Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.
Recommended Stories
- Five stocks we like better than Aytu BioPharma
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- Dividend Capture Strategy: What You Need to Know
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Want to see what other hedge funds are holding AYTU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aytu BioPharma, Inc. (NASDAQ:AYTU – Free Report).
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.